Company intelligence / Profile preview
Foresee Pharmaceuticals
- Ownership
- Private
- Development stage
- Commercial
Overview
Foresee’s lead product CAMCEVI® (leuprolide) has been approved for prostate cancer. Other pipeline assets are in various stages from preclinical to Phase II trials, targeting oncology, respiratory diseases, neurology/psychiatry disorders, and rare inflammatory conditions.
- Therapeutic areas
- PulmonologyCardiovascularEndocrinologyImmunologyOncologyNeurology
- Modalities
- Stabilized Injectable Formulation (SIF) depot technology (long acting injectables)New Chemical Entities (NCEs)Small molecules (e.g., MMP12 inhibitors)Peptide drugs (e.g., leuprolide, triptorelin)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Foresee Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foresee Pharmaceuticals.